Results From 8,000 Patient Trial Confirm VolitionRX's Novel Blood Test Can Accurately Detect Colorectal Cancer And Reduce Colonoscopies

At the Digestive Disease Week 2017 (DDW) in Chicago, VolitionRx Limited (NYSE MKT: VNRX) presented results that continue to show that the Nu.QTM Colorectal Cancer Screening Triage Test reduces the total number of colonoscopy referrals while maintaining high sensitivity for cancer detection.

"We have successfully completed this key clinical milestone in the launch of our Nu.QTM Triage product. This study, with the total cohort totalling just under 8000 subjects demonstrates that the Nu.QTM Triage test was able to prevent 24.5% of colonoscopies and detect almost 95% of colorectal cancers and 87.9% of high-risk adenomas. It further strengthens the case for the Nu.QTM Colorectal Cancer Screening Triage test to be incorporated into colorectal cancer screening programs," said Louise Day, Chief Marketing and Communications Officer at Volition.

Professor Hans Jorgen Nielsen from Hvidovre Hospital, University of Copenhagen, commented, "These results, from a very large data set, confirm that the Nu.QTM Triage test has the potential to accelerate the diagnosis of colorectal cancer, by reducing the number of unnecessary colonoscopies being performed thereby allowing more people to be screened quickly and effectively."

The presentation from the DDW can be found and downloaded at www.volitionrx.com

About Volition

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.

As cancer screening programs become more and more widespread, our products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, New York, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

For more information about Volition, visit Volition's website (http://www.volitionrx.com) or connect with us via:

Back to news